 Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to 140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between 15 and 17 a share. 